An Update on Pediatric Cardiomyopathy

被引：21
作者：
Choudhry S. [1 ]
Puri K. [1 ]
Denfield S.W. [1 ]
机构：
[1] Department of Pediatrics, Section of Pediatric Cardiology, Texas Children’s Hospital, Baylor College of Medicine, 6651 Main St, Houston, 77030, TX
来源：
Current Treatment Options in Cardiovascular Medicine | 2019年 / 21卷 / 8期
关键词：
Dilated; Heart failure; Hypertrophic; Non-compaction; Pediatric cardiomyopathy; Restrictive;
D O I：
10.1007/s11936-019-0739-y
中图分类号：
学科分类号：
摘要：
Purpose of review: This review summarizes the clinical characteristics and updated outcomes of primary pediatric cardiomyopathies including dilated (DCM), hypertrophic (HCM), and restrictive cardiomyopathy (RCM), and briefly discusses left ventricular non-compaction (LVNC) and arrhythmogenic cardiomyopathy (ACM), primarily arrythmogenic right ventricular cardiomyopathy (ARVC). Recent findings: Pediatric cardiomyopathies are diseases of the heart muscle with an estimated annual incidence of 1.1–1.5 cases per 100,000. They are progressive in nature and are frequently caused by a genetic mutation causing a structural abnormality in the myocyte. Dilated cardiomyopathy, characterized by left ventricular dilation and systolic dysfunction with normal left ventricular wall thickness, accounts for about 50–60% of all pediatric cardiomyopathy cases. This is followed by hypertrophic cardiomyopathy accounting for about 40%, characterized by abnormally thickened myocardium in the absence of another cause of hypertrophy with non-dilated left ventricle. Left ventricular non-compaction and restrictive cardiomyopathy each account for about 5% of the cases. Genetic mutations play a dominant role in the development of pediatric cardiomyopathies. While treatment for congestive heart failure and arrhythmias alleviates symptoms, it has not been shown to reduce the risk of sudden death. The 5-year transplant-free survival of DCM, HCM, RCM, and LVNC are 50%, 90%, 30%, and 60% respectively. Summary: Pediatric cardiomyopathies while not common they are a significant cause of morbidity and mortality in afflicted children. Dilated forms are the most common followed by hypertrophic, left ventricular non-compaction, and restrictive cardiomyopathies. Arrhythmogenic cardiomyopathies tend to be diagnosed later in the teenage years. Treatment typically follows adult recommendations for which there is significantly more data on treatment benefits, although the indications for ICD placement in children remain even less clear, other than for secondary prevention. © 2019, Springer Science+Business Media, LLC, part of Springer Nature.
引用
收藏
相关论文
共 82 条
  • [41] Farhad H., Seidelmann S.B., Vigneault D., Abbasi S.A., Yang E., Day S.M., Colan S.D., Russell M.W., Towbin J., Sherrid M.V., Canter C.E., Shi L., Jerosch-Herold M., Bluemke D.A., Ho C., Neilan T.G., Left atrial structure and function in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy, J Cardiovasc Magn Reson, 19, 1, (2017)
  • [42] Maron M.S., Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy, J Cardiovasc Magn Reson, 14, 1, (2012)
  • [43] Axelsson Raja A., Farhad H., Valente A.M., Couce J.P., Jefferies J.L., Bundgaard H., Zahka K., Lever H., Murphy A.M., Ashley E., Day S.M., Sherrid M.V., Shi L., Bluemke D.A., Canter C.E., Colan S.D., Ho C.Y., Prevalence and progression of late gadolinium enhancement in children and adolescents with hypertrophic cardiomyopathy, Circulation., 138, 8, pp. 782-792, (2018)
  • [44] Maurizi N., Passantino S., Spaziani G., Girolami F., Arretini A., Targetti M., Pollini I., Tomberli A., Pradella S., Calabri G.B., Vinattieri V., Bertaccini B., Leone O., De Simone L., Rapezzi C., Marchionni N., Cecchi F., Favilli S., Olivotto I., Long-term outcomes of pediatric-onset hypertrophic cardiomyopathy and age-specific risk factors for lethal arrhythmic events, JAMA Cardiol, 3, 6, pp. 520-525, (2018)
  • [45] Maron B.J., Spirito P., Ackerman M.J., Casey S.A., Semsarian C., Estes N.A., Shannon K.M., Ashley E.A., Day S.M., Pacileo G., Formisano F., Devoto E., Anastasakis A., Bos J.M., Woo A., Autore C., Pass R.H., Boriani G., Garberich R.F., Almquist A.K., Russell M.W., Boni L., Berger S., Maron M.S., Link M.S., Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy, J Am Coll Cardiol, 61, 14, pp. 1527-1535, (2013)
  • [46] Decker J.A., Rossano J.W., Smith E.O., Cannon B., Clunie S.K., Gates C., Jefferies J.L., Kim J.J., Price J.F., Dreyer W.J., Towbin J.A., Denfield S.W., Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children, J Am Coll Cardiol, 54, 3, pp. 250-254, (2009)
  • [47] Hoedemakers S., Vandenberk B., Liebregts M., Bringmans T., Vriesendorp P., Willems R., Van Cleemput J., Long-term outcome of conservative and invasive treatment in patients with hypertrophic obstructive cardiomyopathy, Acta Cardiol, 17, pp. 1-9, (2018)
  • [48] Schleihauf J., Cleuziou J., Pabst von Ohain J., Meierhofer C., Stern H., Shehu N., Mkrtchyan N., Kaltenecker E., Kuhn A., Nagdyman N., Hager A., Seidel H., Lange R., Ewert P., Wolf C.M., Clinical long-term outcome of septal myectomy for obstructive hypertrophic cardiomyopathy in infants, Eur J Cardiothorac Surg, 53, 3, pp. 538-544, (2018)
  • [49] Altarabsheh S.E., Dearani J.A., Burkhart H.M., Schaff H.V., Deo S.V., Eidem B.W., Ommen S.R., Li Z., Ackerman M.J., Outcome of septal myectomy for obstructive hypertrophic cardiomyopathy in children and young adults, Ann Thorac Surg, 95, 2, pp. 663-669, (2013)
  • [50] Batzner A., Pfeiffer B., Neugebauer A., Aicha D., Blank C., Seggewiss H., Survival after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy, J Am Coll Cardiol, 72, 24, pp. 3087-3094, (2018)
123456789